Aissen P.'s scientific contributions

What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.

It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.

If you're a ResearchGate member, you can follow this page to keep up with this author's work.

If you are this author, and you don't want us to display this page anymore, please let us know.

Publication (1)

Cite
Download full-text

Citations

... However, in November 2007, tramiprosate was rejected for further pharmaceutical development because of a lack of proven efficacy in a phase III human clinical trial (Carter et al., 2010). However, while clinical trials of tramiprosate in mild- to-moderate AD have not shown therapeutic efficacy, post-hoc analyses have shown some significantly positive outcomes on secondary endpoints and in some particular subgroups of patients (Aisen et al., 2011;Caltagirone et al., 2012). In particular, the disease-modifying potential is highlighted in APOE4 allele carrier patients by the observed cognitive benefits (Caltagirone et al., 2012;Abushakra et al., 2017). ...
Reference: Heparan Sulfate as a Therapeutic Target in Tauopathies: Insights From Zebrafish
View full-text